P329G-targeting CAR T cell therapy - Roche
Alternative Names: Anti-P329G CAR T cell therapy - RocheLatest Information Update: 07 Feb 2024
At a glance
- Originator Roche
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Acute myeloid leukaemia